Reading CRMD? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CRMD free→Reading CRMD? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CRMD free→QuarterlyIQ Insights · CRMD
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Regulation FD Disclosure On June 8, 2026, CorMedix, Inc. (the “Company”) issued a press release on the decision by the United States Court of Appeals for the Federal Circuit in Melinta Therapeutics, LLC, et al. v. Nexus Pharmaceuticals, Inc. , which affirmed the district court’s judgment that Nexus Pharmaceuticals Inc.’s generic minocycline product infringed two of the Company’s patents and rejected Nexus’s invalidity challenge. A copy of the press release is furnished as Exhibit 99.1, attach…
Results of Operations and Financial Condition On May 14, 2026, CorMedix Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor sh…
Regulation FD Disclosure On April 27, 2026, CorMedix, Inc. (the “Company” or “CorMedix”) issued a press release announcing an update related to the initial readout of topline data for the Phase III study (ReSPECT) assessing REZZAYO® (rezafungin for injection) for prophylaxis of invasive fungal infections. A copy of the press release is furnished as Exhibit 99.1, attached hereto. The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 o…
Regulation FD Disclosure On March 6, 2026, CorMedix, Inc. (the “Company” or “CorMedix”) released an updated investor presentation, which is furnished as Exhibit 99.1, attached hereto. CorMedix is also reaffirming the guidance it previously provided in its press release, dated January 8, 2026, that the Company currently estimates full-year 2027 DefenCath sales in the range of $100 million to $140 million, notwithstanding an inadvertent statement regarding this guidance on its March 5, 2026 ear…
Results of Operations and Financial Condition On March 5, 2026, CorMedix Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilitie…
Results of Operations and Financial Condition. On January 8, 2026, CorMedix Inc. (the “Company”) issued a press release announcing its preliminary financial results for the quarter and year ended December 31, 2025. The preliminary results are subject to the completion of audit and accounting procedures and are therefore subject to adjustment. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02 (including Exh…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 5, 2026, the Company entered into an amended and restated executive employment agreement (the “A&R Employment Agreement”) with Joseph Todisco, the Company’s Chief Executive Officer. Pursuant to the A&R Employment Agreement, Mr. Todisco will continue to serve as the Company’s Chief Executive Officer and will also serve as the Chairman of…
Results of Operations and Financial Condition On November 12, 2025, CorMedix Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that sectio…
Results of Operations and Financial Condition. On October 20, 2025, CorMedix Inc. (the “Company”) issued a press release announcing its preliminary financial results for the quarter ended September 30, 2025. The preliminary results are subject to the completion of accounting procedures and are therefore subject to adjustment. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02, including the press release at…
Entry into a Material Definitive Agreement. On August 12, 2025, CorMedix Inc. (the “Company”) completed its previously announced offering of $150,000,000 aggregate principal amount of its convertible senior notes due 2030 (the “Notes”) in a private placement, exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). Further information about the Notes (including the terms thereof) is contained in the Company’s Current Report on Form…
of Form 8-K, is hereby incorporated by reference herein. The offer and sale of the Notes was made in reliance on the exemption afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) and corresponding provisions of state securities or “blue sky” laws. The Notes, and the shares of the Company’s common stock (“Common Stock”) issuable upon conversion of the Notes, have not been registered under the Securities Act or any state securities laws and may not be of…
Regulation FD Disclosure. On August 7, 2025, the Company issued a press release announcing the execution of the Merger Agreement and the signing of subscription agreements relating to the Convertible Notes Offering. Pursuant to Regulation FD, a copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.2 and incorporated by reference herein. Furnished as Exhibit 99.3 and Exhibit 99.4 and incorporated herein by reference are selected financial information of Meli…
Entry into a Material Definitive Agreement. Merger Agreement On August 7, 2025, CorMedix Inc., a Delaware corporation (the “Company,” “CorMedix,” “we,” “our” and “us”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Melinta Therapeutics, LLC, a Delaware limited liability company (“Melinta”), Coriander BidCo LLC, a Delaware limited liability company and a wholly owned subsidiary of the Company (“Merger Sub”), and Deerfield Private Design Fund IV, L.P., a Delaware li…
Results of Operations and Financial Condition On August 7, 2025, the Company issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall i…
of Form 8-K, is hereby incorporated by reference herein. The offer and sale of the securities issuable in the Merger (including any Merger Warrant Shares), any securities issuable pursuant to the Contingent Payment Agreement (including any shares of Common Stock or shares of Common Stock underlying any pre-funded warrants) and the Convertible Notes Offering are being made in reliance on the exemption afforded by Section 4(a)(2) of the Securities Act and corresponding provisions of state secur…
Other Information. On August 6, 2025, the Company entered into Subscription Agreements with certain investors in connection with the Convertible Notes Offering. A form of the Subscription Agreement is attached hereto as Exhibit 99.5 and incorporated by reference herein. Forward-Looking Statements This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of…
Other Events. On June 26, 2025, CorMedix Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with RBC Capital Markets, LLC, as representative of the several underwriters named therein (the “Underwriters”), relating to the issuance and sale of an aggregate of 6,604,507 shares (the “Firm Shares”) of the Company’s common stock, par value $0.001 per share (“Common Stock”), to the Underwriters (the “Offering”). Pursuant to the Underwriting Agreement, the Comp…
Results of Operations and Financial Condition On May 6, 2025, CorMedix Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor sha…
Changes in Registrant’s Certifying Accountant Based on information provided by Marcum LLP (“Marcum”), the independent registered public accounting firm of CorMedix Inc. (the “Company”), CBIZ CPAs P.C. (“CBIZ CPAs”) acquired the attest business of Marcum, effective November 1, 2024. Marcum continued to serve as the Company’s independent registered public accounting firm through April 17, 2025. On April 17, 2025, Marcum resigned as the Company’s independent registered public accounting firm, an…
Results of Operations and Financial Condition On April 8, 2025, CorMedix Inc. (the “Company”) issued a press release announcing its preliminary financial results for the quarter ended March 31, 2025 and provided a business update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Ex…
Results of Operations and Financial Condition On March 25, 2025, CorMedix Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabiliti…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.